CRC Research Update — October 30, 2026
Today's colorectal cancer research highlights
braf
A collection of 83 issues
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Skip to content
The CRC Digest
◆ TRIAL DATA
BRAF-directed therapy outperforms EGFR inhibition in metastatic BRAF-mutant CRC
Meta-analysis of 18 randomized trials (11,931 participants) found pooled median overall survival of 22.3 months for BRAF-directed regimens versus 10.1 months for EGFR-directed therapy in first-line treatment. (Journal of Gastrointestinal
CRC Research Update — October 25, 2026
Today's colorectal cancer research highlights
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
Skip to content
The CRC Digest
Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status
In 272 resected colorectal cancers, dMMR/MSI-H was present in 9.6% of tumors and independently associated with younger age, proximal tumor location, and poor differentiation. (Clinical Therapeutics)
This content is informational only
CRC Research Update — October 23, 2026
Today's colorectal cancer research highlights
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Among 83 patients with metastatic colorectal cancer, mutation frequencies were 47% for KRAS, 14.5% for NRAS, and 6% for BRAF; BRAF mutations were significantly more frequent in patients under 50 years
Phase II trial tests anti-EGFR rechallenge in ctDNA-selected metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Phase II trial tests anti-EGFR rechallenge in ctDNA-selected metastatic CRC
The ROMANCE trial is randomizing 150 patients with circulating tumor DNA-negative hyperselected metastatic colorectal cancer to irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line therapy, aiming to improve objective response
CRC Research Update — October 20, 2026
Today's colorectal cancer research highlights
PIK3CA and BRAF mutations linked to worse outcomes in RAS wild-type mCRC on anti-EGFR therapy
Skip to content
The CRC Digest
PIK3CA and BRAF mutations linked to worse outcomes in RAS wild-type mCRC on anti-EGFR therapy
A meta-analysis of 1,478 RAS wild-type mCRC patients found PIK3CA mutations were associated with significantly worse PFS (HR 1.38) and OS (HR 1.58), while BRAF mutations
CRC Research Update — October 15, 2026
Today's colorectal cancer research highlights